-
1 week ago | 
labiotech.eu | Jules Adam
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*PhoneThis field is for validation purposes and should be left unchanged. Interleukins — a group of signaling proteins that help immune cells communicate — have long been recognized as powerful tools in modulating immune responses.
-
2 weeks ago | 
labiotech.eu | Jules Adam
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*EmailThis field is for validation purposes and should be left unchanged. Gene therapy has been a very prolific technology across multiple indications, but what about skin diseases? Some conditions, like psoriasis, affect millions worldwide and can lead to chronic discomfort and social stigma.
-
3 weeks ago | 
podcast.labiotech.eu | Jules Adam
There are cell therapies, gene therapies, and biologics – and then there is Immusoft. Immusoft sits at the nexus point of some of the most innovative approaches in biopharma, and their Immune System Programming platform is unique in its capacity to address the rare disease, MPS I.
-
3 weeks ago | 
labiotech.eu | Jules Adam
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*NameThis field is for validation purposes and should be left unchanged. Outsourcing to a contract development and manufacturing organization (CDMO) is a critical step for many biotech companies aiming to advance their programs without building costly internal infrastructure.
-
1 month ago | 
labiotech.eu | Jules Adam
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*CommentsThis field is for validation purposes and should be left unchanged. In the heat of the COVID-19 crisis, a wave of vaccine companies stepped into the spotlight with unprecedented speed and visibility.
-
1 month ago | 
labiotech.eu | Jules Adam
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*PhoneThis field is for validation purposes and should be left unchanged. Genome sequencing is the process of determining the complete DNA sequence of an organism’s genome, a step-by-step decoding of all the genetic instructions.
-
1 month ago | 
labiotech.eu | Jules Adam
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*CommentsThis field is for validation purposes and should be left unchanged. Biotech companies have always been global at their core. From running clinical trials across continents to delivering therapies internationally, success in these industries also depends on crossing borders seamlessly.
-
1 month ago | 
labiotech.eu | Jules Adam
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*NameThis field is for validation purposes and should be left unchanged. Biotech companies have always been global at their core. From running clinical trials across continents to delivering therapies internationally, success in these industries also depends on crossing borders seamlessly.
-
1 month ago | 
labiotech.eu | Jules Adam
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*EmailThis field is for validation purposes and should be left unchanged. Over four decades since its discovery, human immunodeficiency virus (HIV) remains one of the most challenging infectious diseases.
-
1 month ago | 
labiotech.eu | Jules Adam
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*EmailThis field is for validation purposes and should be left unchanged. A fresh take on gene-editing, centered on engineered recombinases, emerges as Brink Therapeutics, a Paris-based biotech startup, secures €3.5 million ($4 billion) in seed funding to advance its platform.
